Bcr-abl promotes pten downregulation in chronic myeloid leukemia

19Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the t(9;22) translocation coding for the chimeric protein p210 BCR-ABL. The tumor suppressor PTEN plays a critical role in the pathogenesis of CML chronic phase, through non genomic loss of function mechanisms, such as protein down-regulation and impaired nuclear/cytoplasmic shuttling. Here we demonstrate that BCR-ABL promotes PTEN downregulation through a MEK dependent pathway. Furthermore, we describe a novel not recurrent N212D-PTEN point mutation found in the EM2 blast crisis cell line.

Cite

CITATION STYLE

APA

Panuzzo, C., Crivellaro, S., Carrà, G., Guerrasio, A., Saglio, G., & Morotti, A. (2014). Bcr-abl promotes pten downregulation in chronic myeloid leukemia. PLoS ONE, 9(10). https://doi.org/10.1371/journal.pone.0110682

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free